[2]. Julien Dugal-Tessier, et al.Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates.J Clin Med.2021 Feb 18;10(4):838.doi: 10.3390/jcm10040838.

[3]. Victor Lehot, et al.Non-specific interactions of antibody-oligonucleotide conjugates with living cells.Sci Rep.2021 Mar 15;11(1):5881.doi: 10.1038/s41598-021-85352-w.

[4]. K Sreedurgalakshmi, et al.Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in Sensitizing the s Toward Gefitinib.Technol Cancer Res Treat.2021 Jan-Dec;20:15330338211041453.doi: 10.1177/15330338211041453.

[5]. Nicole B umer, et al.Antibody-coupled siRNA as an efficient method forin vivomRNA knockdown.Nat Protoc.2016 Jan;11(1):22-36.doi: 10.1038/nprot.2015.137.

[6]. Hua Lu, et al.Site-specific antibody-polymer conjugates for siRNA delivery.JAm Chem Soc.2013 Sep 18;135(37):13885-91.doi: 10.1021/ja4059525.

[7]. Patrick J Kennedy, et al.Antibodies and associates: Partners in targeted drug delivery.Pharmacol Ther.2017 Sep;177:129-145.doi: 10.1016/j.pharmthera.2017.03.004.

[8]. Guizhi Zhu, et al.Aptamer-Drug Conjugates.Bioconjug Chem.2015 Nov 18;26(11):2186-97.doi: 10.1021/acs.bioconjchem.5b00291.

[9]. Tsukasa Sugo, et al.Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles.J Control Release.2016 Sep 10;237:1-13.doi: 10.1016/j.jconrel.2016.06.036.

[10]. Asher Mullard.Antibody-oligonucleotide conjugates enter the clinic.Nat Rev DrugDiscov.2022 Jan;21(1):6-8.doi: 10.1038/d41573-021-00213-5.